Table 1 Datation regarding the MR imaging pps
From: The safety and efficacy of Glubran 2 as biliostatic agent in liver resection
mCRC patients (no.=205) | Control patients (no.=113) | P value | |
|---|---|---|---|
Demographics | |||
Gender | Men 89 (43.4%) | Men 64 (56.6%) | 0.89 |
Women 116 (56.6%) | Women 49 (43.4%) | 0.89 | |
Age | Mean, 56 years | Mean, 48 years | 0.74 |
Range, 33-80 years | Range, 35-78 years | ||
Primary cancer site | |||
Colon | 94 (45.9%) | 52 (46%) | 0.92 |
Rectum | 111 (54.1%) | 61 (54%) | 0.92 |
History of chemotherapy | 205 (100 %) | 113 (100%) | 0.99 |
Chemotherapy protocol | mFOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) plus bevacizumab 205 (100%) | mFOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) plus bevacizumab 113 (100%) | |
Liver metastases | |||
Number | 1075 | 452 | |
mean 4 per patient | mean 5 per patient | ||
range 1-7 per patient | range 2-6 per patient | ||
Largest diameter | mean 32 mm | mean 28 mm | |
range 8-64 mm | range 10-54 mm | ||
Complications | |||
Biloma | 27 (13%) | 18 (16%) | 0.054 |
Bile leakage | 2 (1%) | 3 (2.6%) | 0.001 |